Liquid biopsy could predict who benefits from Post-Chemo breast cancer pill
NCT ID NCT04768426
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study tests a simple blood test (liquid biopsy) to see if it can tell which triple-negative breast cancer patients will benefit from the drug capecitabine after standard chemotherapy. About 40 adults with leftover cancer after chemo will give blood samples before and during treatment. The goal is to learn if tracking tumor DNA in the blood can help personalize future treatments and reduce the risk of cancer coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGStanford, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?